Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

NK cell-based cancer immunotherapy.

John Stagg1, Mark J Smyth

  • 1Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.

Drug News & Perspectives
|May 24, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER<sup>+</sup>HER2<sup>-</sup> breast cancer: a randomized phase 2 trial.

Nature medicine·2026
Same author

Descriptive study of stromal expression of CD73 in ductal carcinoma in situ of the breast.

Discover oncology·2026
Same author

Targeting PAR-2 with a negative allosteric modulator increases tumor antigen presentation and potentiates anti-PD-1 immunotherapy.

Journal for immunotherapy of cancer·2026
Same author

The deubiquitinase USP17 regulates the expression and activity of the oncogenic driver β-catenin in colorectal cancer.

Oncogene·2026
Same author

ATP released by ultrasound targeted microbubble cavitation induces vascular inflammation and improves immune checkpoint blockade efficacy.

Theranostics·2025
Same author

The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma.

Cell reports·2025
Same journal

New drug discovery and development in India.

Drug news & perspectives·2013
Same journal

Are we living in the end of the blockbuster drug era?

Drug news & perspectives·2010
Same journal

Molecule of the Month. TAK-875.

Drug news & perspectives·2010
Same journal

Epigenetic alterations of tumor marker microRNAs: towards new cancer therapies.

Drug news & perspectives·2010
Same journal

Electroporation: a promising method for the nonviral delivery of DNA vaccines in humans?

Drug news & perspectives·2010
Same journal

Trioxaquines: hybrid molecules for the treatment of malaria.

Drug news & perspectives·2010
See all related articles

Cancer immunotherapies are advancing, with natural killer (NK) cells emerging as key players. Harnessing NK cell antitumor activity shows promise for new cancer treatments.

Area of Science:

  • Immunology
  • Oncology
  • Cancer Research

Background:

  • Spontaneous antitumor immune responses observed in cancer patients highlight the immune system's role in malignancy prevention.
  • Research in cancer immunotherapies is rapidly expanding, seeking to leverage immune system components to eliminate established cancers.

Purpose of the Study:

  • To review the critical role of natural killer (NK) cells in controlling tumor growth.
  • To discuss the development of novel cancer therapies that utilize NK cell-mediated antitumor activity.

Main Methods:

  • Review of existing literature on NK cell biology and function in cancer.
  • Analysis of current and emerging immunotherapy strategies involving NK cells.

Main Results:

Related Experiment Videos

  • NK cells are increasingly recognized as crucial mediators in the innate and adaptive immune response against tumors.
  • Understanding NK cell regulatory mechanisms is paving the way for new immunotherapeutic approaches.

Conclusions:

  • NK cells are pivotal in bridging innate and adaptive immunity for tumor control.
  • Harnessing NK cell antitumor activity represents a promising avenue for developing effective cancer immunotherapies.